ABM Unveils Spheroid & Organoid Medium Portfolio to Revolutionize 3D Culture Workflows for Drug Discovery and Disease Modeling

ABM (via Facebook) International

Overview

ABM has launched a new Spheroid & Organoid Medium portfolio designed to robustly support reproducible and scalable 3D culture workflows for drug discovery and disease modeling. This new product line addresses the increasing importance of organoids as more physiologically relevant models, replacing traditional, less human-relevant systems. Its applications span from early-stage drug screening to personalized medicine and advanced oncology research, poised to reshape the future of drug development.

In Depth

Key Findings

ABM has introduced a new Spheroid & Organoid Medium portfolio poised to revolutionize the fields of drug discovery and disease modeling. This product line is engineered to enable researchers to efficiently implement highly reproducible and scalable 3D culture workflows, thereby overcoming the inherent limitations of conventional 2D cell cultures and animal models. 3D culture systems, such as organoids and spheroids, are gaining critical importance as indispensable tools for deepening our understanding of drug responses and disease mechanisms, owing to their ability to more faithfully recapitulate complex in vivo microenvironments.

Technical/Clinical Details

• Spheroid & Organoid Medium Portfolio: This new range of media is optimized for the long-term culture and maintenance of spheroids and organoids derived from various tissues and organs. With compositions customized for specific cell types and organ models, the media maximize cell viability, proliferation, differentiation, and functionality.
• Enhanced Reproducibility and Scalability: ABM’s media, when combined with standardized protocols, minimize batch-to-batch variability, ensuring high reproducibility. They also support formats suitable for high-throughput screening, thereby enhancing scalability in the drug discovery process.
• Evolution from Traditional Models: Organoids and spheroids enable cells to interact in 3D with each other and with the extracellular matrix. This allows for a more accurate capture of in vivo cellular responses not observed in traditional 2D cultures, offering a significant advantage of higher physiological relevance compared to animal models.
• Broad Application Areas:
  • Drug Screening: Provides more accurate and predictive results for toxicity and efficacy evaluations, reducing the risk of late-stage development failures.
  • Personalized Medicine: Organoids derived from patient-specific iPSCs can predict individual drug responses, aiding in the development of tailored therapies.
  • Advanced Oncology Research: Tumor organoids are utilized for studying cancer heterogeneity, metastasis, and mechanisms of therapeutic resistance, accelerating the development of novel anti-cancer agents.
  • Disease Modeling: Offers high-fidelity models for studying the pathophysiology of various diseases, including genetic disorders and infectious diseases, in vitro.

Background & Context

The fields of drug discovery and disease modeling are continuously evolving with the introduction of new technologies. Traditional model systems have faced challenges such as cost, time, ethical concerns, and a lack of human physiological relevance. 3D cell culture technologies, particularly spheroids and organoids, have emerged as promising solutions to these challenges, with the potential to accelerate the bridge from research to clinic. Market demand for specialized media and reagents to support these advanced models is consequently on the rise.

Strategic Significance & Outlook

ABM’s Spheroid & Organoid Medium portfolio is expected to further promote the adoption and standardization of 3D cell culture technology. This will enable pharmaceutical companies to conduct more efficient and accurate drug screening, ultimately leading to an increase in the number of innovative therapies delivered to patients. As integration with AI and machine learning advances, the analytical capabilities for data derived from these 3D models will improve, enhancing drug discovery predictability. Researchers, engineers, and investors should pay close attention to how advancements in this field will shape the future of biopharmaceutical development.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime